MwanzoATYR • NASDAQ
add
aTyr Pharma Inc
$ 5.38
Baada ya Saa za Kazi:(2.04%)+0.11
$ 5.49
Imefungwa: 6 Jun, 19:57:44 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 5.35
Bei za siku
$ 5.34 - $ 5.52
Bei za mwaka
$ 1.42 - $ 5.75
Thamani ya kampuni katika soko
478.84M USD
Wastani wa hisa zilizouzwa
1.71M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 3.96M | 12.89% |
Mapato halisi | -14.88M | 3.94% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.17 | 26.09% |
EBITDA | -15.61M | 5.18% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 76.35M | -9.64% |
Jumla ya mali | 97.24M | -14.13% |
Jumla ya dhima | 22.38M | -22.73% |
Jumla ya hisa | 74.86M | — |
hisa zilizosalia | 89.00M | — |
Uwiano wa bei na thamani | 6.37 | — |
Faida inayotokana na mali | -40.64% | — |
Faida inayotokana mtaji | -46.13% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -14.88M | 3.94% |
Pesa kutokana na shughuli | -15.42M | 31.10% |
Pesa kutokana na uwekezaji | -4.42M | -225.96% |
Pesa kutokana na ufadhili | 18.63M | 140.98% |
Mabadiliko halisi ya pesa taslimu | -1.21M | 92.43% |
Mtiririko huru wa pesa | -9.71M | 41.99% |
Kuhusu
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Ilianzishwa
1 Jan 2005
Tovuti
Wafanyakazi
61
